GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
Status:
Completed
Trial end date:
2018-04-26
Target enrollment:
Participant gender:
Summary
After a stent procedure, it is common practice to prescribe anti-platelet medication to
prevent the blood from clotting. The main objective of this study is to determine if there is
a better medication strategy to prevent blood from clotting and at the same time minimising
the number of complications.
There are two medication strategies:
- Study group: Dual anti-platelet therapy (ticagrelor combined with aspirin) for 1 month,
and then ticagrelor alone for another 23 months OR
- Control group: Standard treatment, being dual anti-platelet therapy (ticagrelor or
clopidogrel combined with aspirin) for 12 months, and then aspirin alone indefinitely
Phase:
Phase 3
Details
Lead Sponsor:
ECRI bv
Collaborators:
AstraZeneca Biosensors International The Medicines Company